Jennifer Wargo, MD, MMSc - Harnessing the Power of Immunotherapy in Resectable Melanoma: Guidance for Delivering Effective Adjuvant and Neoadjuvant Strategies

Go online to PeerView.com/NHA860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. Immunotherapy is now a highly efficacious management tool
for melanoma, including in resectable stage III/IV disease, where
its use is supported by phase 3 evidence and current practice
guidelines. This “Clinical Consults” activity, taken from a recent
surgical oncology live event, features expert-led case discussions
that illustrate how to deliver effective care with established and
emerging immune-based modalities in surgical settings. Linked mini
lecture segments cover topics such as adjuvant immunotherapy in
stage II/III melanoma; efficacy, safety, and dosing information on
neoadjuvant immunotherapy; and emerging immune-based treatments in
resectable melanoma (eg, PD-1/LAG-3 combinations). Watch today to
learn how to identify optimal candidates for immunotherapy, address
treatment selection and dosing considerations, and effectively
manage immune-related events. Upon completion of this activity,
participants should be better able to: State current evidence and
guideline recommendations surrounding the use of adjuvant and
neoadjuvant immunotherapy for resectable or potentially resectable
melanoma, including stage II, III, and IV disease; Develop a
treatment plan that includes adjuvant and neoadjuvant
immunotherapeutic options for patients with resectable melanoma,
including those with and without BRAF-mutant disease; and Implement
strategies to mitigate immune-related adverse events in patients
with melanoma who are receiving immunotherapy in conjunction with
surgery.